Compare MFA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | ABCL |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | MFA | ABCL |
|---|---|---|
| Price | $9.42 | $4.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $11.05 | $8.40 |
| AVG Volume (30 Days) | 1.4M | ★ 8.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.02 | $21.85 |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $8.78 | $1.94 |
| 52 Week High | $10.57 | $6.52 |
| Indicator | MFA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 47.01 |
| Support Level | $9.38 | $3.96 |
| Resistance Level | $10.26 | $4.84 |
| Average True Range (ATR) | 0.22 | 0.40 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 9.55 | 21.93 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.